Skip to Content
Merck
  • Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.

Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.

Pharmaceutical research (2014-01-31)
Mette U Anby, Hywel D Williams, Orlagh Feeney, Glenn A Edwards, Hassan Benameur, Colin W Pouton, Christopher J H Porter
ABSTRACT

To explore the possibility that age-related changes in physiology may result in differences in drug bioavailability after oral administration of lipid based formulations of danazol. Danazol absorption from lipid formulations with increasing drug load was examined in younger (9 months) and older (8 years) beagles. Age related changes to hepatic function were assessed via changes to systemic clearance and serum bile acid concentrations. Changes to lipolytic enzyme activity and intestinal bile salt concentration were evaluated using in vitro lipolysis. Drug exposure increased linearly with dose in younger animals. In older animals, bioavailability increased with increasing dose to a tipping point, beyond which bioavailability reduced (consistent with initiation of precipitation). No differences in hepatic function were apparent across cohorts. Changes to enzyme concentrations in lipolysis studies had little impact on drug precipitation/solubilisation. In contrast, higher bile salt concentrations better supported supersaturation at higher drug loads. Differences in animal cohort can have a significant impact on drug absorption from lipid based formulation. For danazol, bioavailability was enhanced under some circumstances in older animals. In vitro experiments suggest that this was unlikely to reflect changes to metabolism or lipolysis, but might be explained by increases in luminal bile salt/phospholipid concentrations in older animals.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium hydroxide solution, 0.1 M
Sigma-Aldrich
Sodium hydroxide solution, 4 M
Sigma-Aldrich
Sodium hydroxide solution, 7 M
Sigma-Aldrich
Sodium hydroxide solution, 6 M
Sigma-Aldrich
Sodium hydroxide solution, 0.01 M
Sigma-Aldrich
Sodium hydroxide solution, 1 M
Sigma-Aldrich
Sodium hydroxide solution, 0.05 M
Supelco
Sodium hydroxide concentrate, 0.1 M NaOH in water (0.1N), Eluent concentrate for IC
Supelco
Progesterone, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sodium hydroxide, BioUltra, for luminescence, ≥98.0% (T), pellets
Sigma-Aldrich
Sodium hydroxide solution, BioUltra, for molecular biology, 10 M in H2O
Supelco
Progesterone, VETRANAL®, analytical standard
Supelco
Sodium hydroxide solution, 49-51% in water, eluent for IC
Sigma-Aldrich
Ethylene sulfite, 98%
Sigma-Aldrich
Progesterone, ≥99%
Sigma-Aldrich
Progesterone, meets USP testing specifications
Sigma-Aldrich
Progesterone, γ-irradiated, BioXtra, suitable for cell culture
Sigma-Aldrich
Sodium hydroxide solution, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
Progesterone, powder, BioReagent, suitable for cell culture
USP
Progesterone, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Sodium hydroxide, ultra dry, powder or crystals, 99.99% trace metals basis
Progesterone, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium hydroxide solution, 0.2 M
Sigma-Aldrich
Sodium hydroxide, SAJ first grade, ≥95.0%
Sigma-Aldrich
3-Ethyl-2,4-pentanedione, mixture of tautomers, 98%
Sigma-Aldrich
Ethylene sulfite, ≥99.0%
Sigma-Aldrich
Sodium hydroxide solution, 50% in H2O
Progesterone for system suitability, European Pharmacopoeia (EP) Reference Standard
Progesterone for peak identification, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium hydroxide, BioXtra, ≥98% (acidimetric), pellets (anhydrous)